Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGT 007

Next Previous
Drug Profile

BGT 007

Alternative Names: BGT-007; BGT007H

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSyngen
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Digestive system neoplasms; Gastrointestinal cancer
  • Clinical Phase Unknown Pancreatic cancer
  • Preclinical Colorectal cancer; Oesophageal cancer
  • No development reported Nasopharyngeal cancer

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for phase-0 development in Nasopharyngeal-cancer(Metastatic disease, Second-line therapy or greater) in China (IV)
  • 07 May 2024 Clinical trials in Pancreatic cancer (Second-line therapy or greater, Late-stage disease) in China (Parenteral) (NCT06478225)
  • 22 Oct 2023 Phase-0 for Digestive system neoplasms (Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT06104215)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top